235 related articles for article (PubMed ID: 24712857)
21. CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.
Dubinski D; Wölfer J; Hasselblatt M; Schneider-Hohendorf T; Bogdahn U; Stummer W; Wiendl H; Grauer OM
Neuro Oncol; 2016 Jun; 18(6):807-18. PubMed ID: 26578623
[TBL] [Abstract][Full Text] [Related]
22. Lenalidomide - current understanding of mechanistic properties.
Tageja N
Anticancer Agents Med Chem; 2011 Mar; 11(3):315-26. PubMed ID: 21426296
[TBL] [Abstract][Full Text] [Related]
23. Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses.
Noonan K; Rudraraju L; Ferguson A; Emerling A; Pasetti MF; Huff CA; Borrello I
Clin Cancer Res; 2012 Mar; 18(5):1426-34. PubMed ID: 22241792
[TBL] [Abstract][Full Text] [Related]
24. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
Görgün G; Samur MK; Cowens KB; Paula S; Bianchi G; Anderson JE; White RE; Singh A; Ohguchi H; Suzuki R; Kikuchi S; Harada T; Hideshima T; Tai YT; Laubach JP; Raje N; Magrangeas F; Minvielle S; Avet-Loiseau H; Munshi NC; Dorfman DM; Richardson PG; Anderson KC
Clin Cancer Res; 2015 Oct; 21(20):4607-18. PubMed ID: 25979485
[TBL] [Abstract][Full Text] [Related]
25. Mn complex-mediated enhancement of antitumor response through modulating myeloid-derived suppressor cells in drug-resistant tumor.
Das S; Banerjee K; Roy S; Majumder S; Chatterjee M; Majumdar S; Choudhuri SK
In Vivo; 2014; 28(5):909-18. PubMed ID: 25189907
[TBL] [Abstract][Full Text] [Related]
26. Lenalidomide in the treatment of multiple myeloma: a review.
Armoiry X; Aulagner G; Facon T
J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408
[TBL] [Abstract][Full Text] [Related]
27. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.
Benson DM; Bakan CE; Zhang S; Collins SM; Liang J; Srivastava S; Hofmeister CC; Efebera Y; Andre P; Romagne F; Bléry M; Bonnafous C; Zhang J; Clever D; Caligiuri MA; Farag SS
Blood; 2011 Dec; 118(24):6387-91. PubMed ID: 22031859
[TBL] [Abstract][Full Text] [Related]
28. Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia.
Lee BN; Gao H; Cohen EN; Badoux X; Wierda WG; Estrov Z; Faderl SH; Keating MJ; Ferrajoli A; Reuben JM
Cancer; 2011 Sep; 117(17):3999-4008. PubMed ID: 21858802
[TBL] [Abstract][Full Text] [Related]
29. Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma.
Noonan KA; Ghosh N; Rudraraju L; Bui M; Borrello I
Cancer Immunol Res; 2014 Aug; 2(8):725-31. PubMed ID: 24878583
[TBL] [Abstract][Full Text] [Related]
30. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models.
Cho SF; Lin L; Xing L; Li Y; Wen K; Yu T; Hsieh PA; Munshi N; Wahl J; Matthes K; Friedrich M; Arvedson T; Anderson KC; Tai YT
Blood Adv; 2020 Sep; 4(17):4195-4207. PubMed ID: 32898244
[TBL] [Abstract][Full Text] [Related]
31. New immunomodulatory drugs in myeloma.
Lacy MQ
Curr Hematol Malig Rep; 2011 Jun; 6(2):120-5. PubMed ID: 21327565
[TBL] [Abstract][Full Text] [Related]
32. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J
Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626
[TBL] [Abstract][Full Text] [Related]
33. Polyclonal immune activation and marrow plasmacytosis in multiple myeloma patients receiving long-term lenalidomide therapy: incidence and prognostic significance.
Zamarin D; Devlin SM; Arcila ME; Landau H; Lesokhin A; Lendvai N; Chung DJ; Chimento D; Weltz J; Babu D; Giralt S; Hassoun H
Leukemia; 2013 Dec; 27(12):2422-4. PubMed ID: 23608883
[No Abstract] [Full Text] [Related]
34. Evaluation of regulatory T cells (Tregs) alterations in patients with multiple myeloma treated with bortezomib or lenalidomide plus dexamethasone: correlations with treatment outcome.
Hadjiaggelidou C; Mandala E; Terpos E; Yiannaki E; Markala D; Triantafyllou T; Papatheodorou A; Gkastari V; Verrou E; Papanikolaou A; Konstantinidou P; Katodritou E
Ann Hematol; 2019 Jun; 98(6):1457-1466. PubMed ID: 30895351
[TBL] [Abstract][Full Text] [Related]
35. Immunomodulation as a therapeutic strategy in the treatment of multiple myeloma.
Mitsiades CS; Chen-Kiang S
Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S5-13. PubMed ID: 23806982
[TBL] [Abstract][Full Text] [Related]
36. Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma.
Ou DL; Chang CJ; Jeng YM; Lin YJ; Lin ZZ; Gandhi AK; Liao SC; Huang ZM; Hsu C; Cheng AL
J Gastroenterol Hepatol; 2014 Dec; 29(12):2021-31. PubMed ID: 25160036
[TBL] [Abstract][Full Text] [Related]
37. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.
Zhu YX; Kortuem KM; Stewart AK
Leuk Lymphoma; 2013 Apr; 54(4):683-7. PubMed ID: 22966948
[TBL] [Abstract][Full Text] [Related]
38. Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy.
Chan AC; Neeson P; Leeansyah E; Tainton K; Quach H; Prince HM; Harrison SJ; Godfrey DI; Ritchie D; Berzins SP
Clin Exp Immunol; 2014 Jan; 175(1):49-58. PubMed ID: 24032527
[TBL] [Abstract][Full Text] [Related]
39. Multiple myeloma and immunomodulation: regulating the regulatory cells.
Kasyapa CS; Sher T; Chanan-Khan AA
Leuk Lymphoma; 2012 Jul; 53(7):1253-4. PubMed ID: 22397723
[No Abstract] [Full Text] [Related]
40. Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma.
Rychak E; Mendy D; Shi T; Ning Y; Leisten J; Lu L; Miller K; Narla RK; Orlowski RZ; Raymon HK; Bjorklund CC; Thakurta A; Gandhi AK; Cathers BE; Chopra R; Daniel TO; Lopez-Girona A
Br J Haematol; 2016 Mar; 172(6):889-901. PubMed ID: 26914976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
